Skip to main content

Site notifications

CEENU lomustine capsules 10mg (BMS Canada)

Section 19A approved medicine
CEENU lomustine capsules 10mg (BMS Canada)
Section 19A approval holder
Pro Pharmaceuticals Group Pty Ltd ABN 20 605 457 430
Phone
1300 077 674
Approved until
Status
Current
Medicines in short supply/unavailable
CEENU lomustine 10mg capsule bottle - ARTG 19252
Indication(s)

Lomustine may be used for the treatment of:

  1. Brain tumours (primary and secondary)
  2. Hodgkin's disease (as secondary therapy). Lomustine is used in addition to appropriate surgical and/or radiotherapeutic procedures or as a component of various chemotherapeutic regimens in the palliative treatment of primary and metastatic brain tumours. Lomustine containing combinations should be used as alternative therapy in the treatment of disseminated Hodgkin's disease in patients refractory to other established treatment regimens.
Images
Picture of CEENU lomustine capsules 10mg - carton

Help us improve the Therapeutic Goods Administration site